De Novo Variants Disturbing the Transactivation Capacity of POU3F3 Cause a Characteristic Neurodevelopmental Disorder.


Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
01 08 2019
Historique:
received: 10 02 2019
accepted: 07 06 2019
pubmed: 16 7 2019
medline: 17 3 2020
entrez: 16 7 2019
Statut: ppublish

Résumé

POU3F3, also referred to as Brain-1, is a well-known transcription factor involved in the development of the central nervous system, but it has not previously been associated with a neurodevelopmental disorder. Here, we report the identification of 19 individuals with heterozygous POU3F3 disruptions, most of which are de novo variants. All individuals had developmental delays and/or intellectual disability and impairments in speech and language skills. Thirteen individuals had characteristic low-set, prominent, and/or cupped ears. Brain abnormalities were observed in seven of eleven MRI reports. POU3F3 is an intronless gene, insensitive to nonsense-mediated decay, and 13 individuals carried protein-truncating variants. All truncating variants that we tested in cellular models led to aberrant subcellular localization of the encoded protein. Luciferase assays demonstrated negative effects of these alleles on transcriptional activation of a reporter with a FOXP2-derived binding motif. In addition to the loss-of-function variants, five individuals had missense variants that clustered at specific positions within the functional domains, and one small in-frame deletion was identified. Two missense variants showed reduced transactivation capacity in our assays, whereas one variant displayed gain-of-function effects, suggesting a distinct pathophysiological mechanism. In bioluminescence resonance energy transfer (BRET) interaction assays, all the truncated POU3F3 versions that we tested had significantly impaired dimerization capacities, whereas all missense variants showed unaffected dimerization with wild-type POU3F3. Taken together, our identification and functional cell-based analyses of pathogenic variants in POU3F3, coupled with a clinical characterization, implicate disruptions of this gene in a characteristic neurodevelopmental disorder.

Identifiants

pubmed: 31303265
pii: S0002-9297(19)30232-0
doi: 10.1016/j.ajhg.2019.06.007
pmc: PMC6698880
pii:
doi:

Substances chimiques

POU Domain Factors 0
POU3F3 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

403-412

Subventions

Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007748
Pays : United States

Informations de copyright

Copyright © 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Références

Eur J Biochem. 2000 Nov;267(21):6413-22
pubmed: 11029584
J Mol Biol. 2000 Oct 6;302(5):1023-39
pubmed: 11183772
Nature. 2001 Oct 4;413(6855):519-23
pubmed: 11586359
Science. 2002 Feb 22;295(5559):1528-32
pubmed: 11859196
Genes Dev. 2002 Jul 15;16(14):1760-5
pubmed: 12130536
Biochem Pharmacol. 2002 Sep;64(5-6):979-84
pubmed: 12213595
Nat Genet. 2004 Aug;36(8):801-8
pubmed: 15284851
Dev Cell. 2006 Dec;11(6):831-44
pubmed: 17141158
Annu Rev Biochem. 2007;76:51-74
pubmed: 17352659
Am J Hum Genet. 2009 Apr;84(4):524-33
pubmed: 19344873
Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10171-6
pubmed: 19520826
Proteins. 2011 Feb;79(2):674-7
pubmed: 21117060
Cereb Cortex. 2013 Nov;23(11):2632-43
pubmed: 22892427
Mol Biol Evol. 2013 Apr;30(4):844-52
pubmed: 23197593
Mol Syndromol. 2014 Jan;5(1):32-5
pubmed: 24550763
J Vis Exp. 2014 May 26;(87):null
pubmed: 24893771
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Science. 1989 Jul 28;245(4916):371-8
pubmed: 2667136
Am J Hum Genet. 2016 Feb 4;98(2):363-72
pubmed: 26833329
Nature. 1989 Jul 6;340(6228):35-41
pubmed: 2739723
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Trends Genet. 2017 Sep;33(9):642-656
pubmed: 28781152
Neuropediatrics. 2018 Dec;49(6):401-404
pubmed: 30199896
Genes Dev. 1993 Dec;7(12B):2483-96
pubmed: 8276233
J Mol Evol. 1996 Sep;43(3):170-8
pubmed: 8703082
Brain Res. 1997 Mar 28;752(1-2):261-8
pubmed: 9106466
J Biol Chem. 1998 Dec 18;273(51):34196-205
pubmed: 9852081

Auteurs

Lot Snijders Blok (L)

Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands; Language and Genetics Department, Max Planck Institute for Psycholinguistics, PO Box 310, 6500AH Nijmegen, the Netherlands; Donders Institute for Brain, Cognition, and Behaviour, PO Box 9104, 6500HE Nijmegen, the Netherlands. Electronic address: lot.snijdersblok@radboudumc.nl.

Tjitske Kleefstra (T)

Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands; Donders Institute for Brain, Cognition, and Behaviour, PO Box 9104, 6500HE Nijmegen, the Netherlands.

Hanka Venselaar (H)

Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands.

Saskia Maas (S)

Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Genetics, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands.

Hester Y Kroes (HY)

Department of Genetics, University Medical Center Utrecht, PO Box 85090, 3508AB Utrecht, the Netherlands.

Augusta M A Lachmeijer (AMA)

Department of Genetics, University Medical Center Utrecht, PO Box 85090, 3508AB Utrecht, the Netherlands.

Koen L I van Gassen (KLI)

Department of Genetics, University Medical Center Utrecht, PO Box 85090, 3508AB Utrecht, the Netherlands.

Helen V Firth (HV)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.

Susan Tomkins (S)

Clinical Genetics Service, University Hospitals Bristol National Health Service Foundation Trust, Bristol BS2 8HW, UK.

Simon Bodek (S)

Clinical Genetics Service, University Hospitals Bristol National Health Service Foundation Trust, Bristol BS2 8HW, UK.
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.

Katrin Õunap (K)

Department of Clinical Genetics, United Laboratories, Tartu University Hospital and Institute of Clinical Medicine, University of Tartu, Tartu 51014, Estonia; Institute of Clinical Medicine, University of Tartu, Tartu 51014, Estonia.

Monica H Wojcik (MH)

The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Division of Newborn Medicine, Division of Genetics, Boston Children's Hospital, Boston, MA 02115, USA.

Christopher Cunniff (C)

Division of Medical Genetics, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10021, USA.

Katherine Bergstrom (K)

Division of Medical Genetics, Department of Pediatrics, Weill Cornell Medicine, New York, NY 10021, USA.

Zoë Powis (Z)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA 92656, USA.

Sha Tang (S)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA 92656, USA.

Deepali N Shinde (DN)

Clinical Genomics, Ambry Genetics, Aliso Viejo, CA 92656, USA.

Catherine Au (C)

Division of Clinical Genetics, Department of Pediatrics, New York Presbyterian Hospital, Columbia University, New York, NY 10032, USA.

Alejandro D Iglesias (AD)

Division of Clinical Genetics, Department of Pediatrics, New York Presbyterian Hospital, Columbia University, New York, NY 10032, USA.

Kosuke Izumi (K)

Division of Human Genetics, the Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

Jacqueline Leonard (J)

Division of Human Genetics, the Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

Ahmad Abou Tayoun (A)

Division of Genomic Diagnostics, the Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

Samuel W Baker (SW)

Division of Genomic Diagnostics, the Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

Marco Tartaglia (M)

Genetics and Rare Diseases Research Division, Bambino Gesù Children Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, 00146 Rome, Italy.

Marcello Niceta (M)

Genetics and Rare Diseases Research Division, Bambino Gesù Children Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, 00146 Rome, Italy.

Maria Lisa Dentici (ML)

Genetics and Rare Diseases Research Division, Bambino Gesù Children Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, 00146 Rome, Italy.

Nobuhiko Okamoto (N)

Department of Medical Genetics, Osaka Women's and Children's Hospital, 840 Murodo-cho, Izumi, Osaka 594-1101, Japan.

Noriko Miyake (N)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.

Naomichi Matsumoto (N)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.

Antonio Vitobello (A)

UF Innovation en Diagnostic Génomique des Maladies Rares, Centre Hospitalier Universitaire Dijon Bourgogne, 21000 Dijon, France; INSERM UMR1231 Génétique des Anomalies du Développement, F-21000 Dijon, France.

Laurence Faivre (L)

INSERM UMR1231 Génétique des Anomalies du Développement, F-21000 Dijon, France; Centre de Référence Maladies Rares « Anomalies du Développement et Syndrome Malformatifs » de l'Est, Centre de Génétique, Hôpital d'Enfants, Fédération Hospitalo-Universitaire Médecine TRANSLationnelle et Anomalies du Développement, Centre Hospitalier Universitaire Dijon Bourgogne, 21000 Dijon, France.

Christophe Philippe (C)

UF Innovation en Diagnostic Génomique des Maladies Rares, Centre Hospitalier Universitaire Dijon Bourgogne, 21000 Dijon, France; INSERM UMR1231 Génétique des Anomalies du Développement, F-21000 Dijon, France.

Christian Gilissen (C)

Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands.

Laurens Wiel (L)

Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands; Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands.

Rolph Pfundt (R)

Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands.

Pelagia Deriziotis (P)

Language and Genetics Department, Max Planck Institute for Psycholinguistics, PO Box 310, 6500AH Nijmegen, the Netherlands.

Han G Brunner (HG)

Human Genetics Department, Radboud University Medical Center, PO Box 9101, 6500HB Nijmegen, the Netherlands; Donders Institute for Brain, Cognition, and Behaviour, PO Box 9104, 6500HE Nijmegen, the Netherlands; Department of Clinical Genetics and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, 6202AZ Maastricht, the Netherlands.

Simon E Fisher (SE)

Language and Genetics Department, Max Planck Institute for Psycholinguistics, PO Box 310, 6500AH Nijmegen, the Netherlands; Donders Institute for Brain, Cognition, and Behaviour, PO Box 9104, 6500HE Nijmegen, the Netherlands. Electronic address: simon.fisher@mpi.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH